← Back to Screener
Summit Therapeutics Inc. Common Stock (SMMT)
Price$25.12
Favorite Metrics
Price vs S&P 500 (26W)2.66%
Price vs S&P 500 (4W)52.89%
Market Capitalization$19.48B
All Metrics
Book Value / Share (Quarterly)$0.85
P/TBV (Annual)6.75x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.42
Price vs S&P 500 (YTD)39.69%
Net Profit Margin (TTM)-9027.08%
EPS (TTM)$-1.01
10-Day Avg Trading Volume3.09M
EPS Excl Extra (TTM)$-1.01
EPS (Annual)$-0.31
ROI (Annual)-56.93%
Net Profit Margin (5Y Avg)-5207.57%
Cash / Share (Quarterly)$0.92
ROA (Last FY)-50.81%
EBITD / Share (TTM)$-1.03
ROE (5Y Avg)-216.65%
Operating Margin (TTM)-8108.33%
Cash Flow / Share (Annual)$-0.42
P/B Ratio29.56x
P/B Ratio (Quarterly)19.76x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)20054.27x
Net Interest Coverage (TTM)-121.35x
ROA (TTM)-181.28%
EPS Incl Extra (Annual)$-0.31
Current Ratio (Annual)9.87x
Quick Ratio (Quarterly)9.78x
3-Month Avg Trading Volume2.65M
52-Week Price Return2.07%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.60
P/S Ratio (Annual)27432.90x
Asset Turnover (Annual)0.00x
52-Week High$36.91
Operating Margin (5Y Avg)-4960.39%
EPS Excl Extra (Annual)$-0.31
CapEx CAGR (5Y)9.36%
26-Week Price Return9.55%
Quick Ratio (Annual)9.78x
13-Week Price Return45.45%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.87x
Enterprise Value$19,252.095
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-2.46%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-11095.77%
Cash / Share (Annual)$0.92
3-Month Return Std Dev68.37%
Net Income / Employee (TTM)$-3
ROE (Last FY)-56.93%
Net Interest Coverage (Annual)-67.22x
EPS Basic Excl Extra (Annual)$-0.31
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-205.12%
P/S Ratio (TTM)20288.92x
Pretax Margin (5Y Avg)-5211.66%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.60
Price vs S&P 500 (52W)-32.56%
Year-to-Date Return43.62%
5-Day Price Return20.48%
EPS Normalized (Annual)$-0.31
ROA (5Y Avg)-99.04%
Net Profit Margin (Annual)-11095.77%
Month-to-Date Return32.49%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-0.31
Operating Margin (Annual)-10153.52%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-117.59%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.01
P/TBV (Quarterly)6.75x
P/B Ratio (Annual)19.76x
Pretax Margin (TTM)-9027.08%
Book Value / Share (Annual)$0.85
Price vs S&P 500 (13W)43.07%
Beta-1.26x
Revenue / Share (TTM)$0.00
ROE (TTM)-208.63%
52-Week Low$13.83
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.96
3.96
3.96
3.87
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SMMTSummit Therapeutics Inc. Common Stock | 20288.92x | — | — | — | $25.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Summit Therapeutics is a biopharmaceutical company focused on developing novel antibiotics for serious infectious diseases. Its lead product candidate, ridinilazole, is an orally administered antibiotic designed to treat Clostridioides difficile infections (CDI). The company operates in the United States and United Kingdom.